Importantly, the approved BCR-ABL and MAP4K4 inhibitory drug bosutinib (Bosulif®) restores endothelial barrier functions and reduces vascular leakage (24), rendering this compound a candidate drug for tumor patients suffering from tumors associated with aberrant MAP4K4 functions. This evidence concerns the gene MAP4K4 and neoplasm.